Living Cell Technologies Limited (LCT) is a biotechnology company dedicated to the innovation, development, and market introduction of regenerative medical therapies. These treatments leverage naturally occurring cells with the aim of restoring physiological functions, particularly within New Zealand. A primary focus for LCT is NTCELL, a novel alginate-coated capsule currently progressing through Phase IIb clinical trials for its application in treating Parkinson's disease.